- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01811394
Ion Irradiation of Sacrococcygeal Chordoma (ISAC)
November 29, 2023 updated by: Klaus Herfarth, MD, Heidelberg University
Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma
The purpose of this study is to evaluate the safety and feasibility of primary hypofractionated irradiation of sacrococcygeal chordoma with carbon ions or protons using the raster scan technique.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this trial is safety and feasibility of hypofractionated irradiation in patients with sacrococcygeal chordoma using protons or carbon ions in raster scan technique for primary or additive treatment after R2 resection.
The evaluation is therefore based on the proportion of treatments without Grade 3-5 toxicity (CTCAE, version 4.0) up to 12 months after treatment and/or discontinuation of the treatment for any reason as primary endpoint.
Local-progression free survival, overall survival and quality of life will be analyzed as secondary end points.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Heidelberg, Germany, 69125
- University of Heidelberg, Radiooncology, HIT
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histological confirmation of sacrococcygeal chordoma
- Karnofsky performance status ≥ 70%
- Patients age 18 - 80 years
- Macroscopic tumour (MRI)
- Written informed consent
Exclusion Criteria:
- Lack of macroscopic tumour
- Tumor extension in craniocaudal direction >16cm
- Metal implants at the level of the tumor which could influence the treatment planning
- Inability of the patient to lie quiet for at least 20 minutes (eg due to pain)
- Prior radiotherapy of the pelvic region
- Simultaneous participation in another trial that could influence the results of the study
- Active medical implants without treatment approval at the time of ion irradiation (eg, cardiac pacemaker, defibrillator)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: protons
16x4GyE protons
|
Treatment is performed using 16 x 4 GyE protons
|
Experimental: Carbon ions
16x4GyE carbon ions
|
Treatment is performed using 16 x 4 GyE carbon ions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety and feasibility of hypofractionated irradiation in patients with sacrococcygeal chordoma using ions (protons or carbon ions) in raster scan technique
Time Frame: From date of treatment start until 12 months after treatment.
|
The evaluation is based on incidence of Grade 3-5 toxicity (NCI-CTC-AE) and/or discontinuation of the treatment for any reason.
Endpoint is the proportion of treatments without Grade 3-5 toxicity (NCI-CTC-AE) up to 12 months after treatment and/or discontinuation of the treatment for any reason
|
From date of treatment start until 12 months after treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
local progression free survival (LPFS)
Time Frame: From date of treatment start until the date of first documented progression in MRI/CT scan assessed up to 12 months.
|
local progression free survival (LPFS) is determined from start of treatment until local progression in imaging (>10% size increase)
|
From date of treatment start until the date of first documented progression in MRI/CT scan assessed up to 12 months.
|
Overall survival (OS)
Time Frame: From date of treatment start until the date of death from any cause assessed up to 12 months.
|
Further objectives are overall survival (OS) from date of treatment start until the date of death from any cause assessed up to 12 months
|
From date of treatment start until the date of death from any cause assessed up to 12 months.
|
Quality of life (QoL)
Time Frame: From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment.
|
Quality of life (QoL) evaluated with EORTC-QLQ30 questionnaire.
|
From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2013
Primary Completion (Actual)
February 1, 2023
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
March 9, 2013
First Submitted That Met QC Criteria
March 12, 2013
First Posted (Estimated)
March 14, 2013
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
November 29, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISAC-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sacral Chordoma
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompletedChordoma | Metastatic Chordoma | Unresectable Chordoma | Locally Advanced ChordomaUnited States
-
M.D. Anderson Cancer CenterRecruitingChordoma | Metastatic Chordoma | Unresectable ChordomaUnited States
-
Institut CurieActive, not recruitingSkull Base Chordoma | Vertebral ChordomaFrance
-
Huashan HospitalBoehringer IngelheimNot yet recruiting
-
Xuanwu Hospital, BeijingRecruiting
-
CNAO National Center of Oncological HadrontherapyDept. of Electronics, Informatics, Bioengineering, Politecnico di Milano,...Recruiting
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI)Active, not recruitingChordoma of Sacrum | Chordoma of Spine | Chordoma of Base of Skull | Chondrosarcoma of the Spine | Chondrosarcoma of the SacrumUnited States
-
Globus Medical IncTerminatedAcute Instabilities Thoracic, Lumbar and Sacral Spine | Chronic Instabilities Thoracic, Lumbar and Sacral Spine | Deformities of the Thoracic, Lumbar and Sacral SpineUnited States
-
Tanta UniversityCompletedCaudal Block | Pediatrics | Sacral Erector Spinae Plane Block | Penile SurgeriesEgypt
Clinical Trials on protons
-
University Hospital HeidelbergRecruitingSoft Tissue SarcomaGermany
-
Heidelberg UniversityRecruitingChordoma | Tumor | TreatmentGermany
-
EBG MedAustron GmbHRecruiting
-
Technische Universität DresdenGerman Cancer Research Center; National Center for Radiation Research in Oncology...RecruitingBrain TumorsGermany
-
Technische Universität DresdenRadiation Oncology Working Group of the German Cancer Society; German Consortium... and other collaboratorsRecruiting
-
Hospices Civils de LyonRecruitingMalignant Tumors as Chordoma, Adenoid Cystic Carcinoma and SarcomaFrance
-
University Hospital HeidelbergRecruitingProstate CancerGermany
-
CNAO National Center of Oncological HadrontherapyRecruiting
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedNon-small Cell Lung Cancer Metastatic | Targetable Oncogenes (EGFR, ALK, ROS1)United States
-
Emory UniversityNational Cancer Institute (NCI)Not yet recruitingResectable Lung Non-Small Cell CarcinomaUnited States